Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib vs gemcitabine vs masitinib + gemcitabine in relapsed or refractory peripheral T‑cell lymphoma
2010-021091-28Phase 2Completed
- Sponsor
- AB Science
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in peripheral T-cell lymphoma (PTCL) and non-Hodgkin lymphoma (NHL) comparing Masitinib + dexamethasone, Gemcitabine + dexamethasone and Masitinib + gemcitabine + dexamethasone (3 arms). Primary endpoint: Overall survival. Started Jun 2014; status: completed.
02
Drugs
masitinibgemcitabinedexamethasone
03
Conditions
peripheral T-cell lymphoma (PTCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2010-021091-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021091-28.